生产企业：OncoC4 Inc.
ONC-841 is a first-in-class anti-SIGLEC-10 antibody developed by OncoC4, currently in a Phase 2 trial for oncology indications and a Phase 1 trial for neurodegenerative diseases. It is part of OncoC4's pipeline of assets with first-in-class and best-in-class potential targeting both novel and well-validated targets across oncology and immunological diseases.
ONC-841 is a first-in-class anti-SIGLEC-10 antibody developed by OncoC4, currently in a Phase 2 trial for oncology indications and a Phase 1 trial for neurodegenerative diseases. It is part of OncoC4's pipeline of assets with first-in-class and best-in-class potential targeting both novel and well-validated targets across oncology and immunological diseases.
first-in-class anti-SIGLEC-10 antibody
